Last reviewed · How we verify
Redemplo (PLOZASIRAN)
Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides.
At a glance
| Generic name | PLOZASIRAN |
|---|---|
| Sponsor | Arrowhead |
| Drug class | APOC-III-directed RNA Interaction [EPC] |
| Target | apoC-III mRNA |
| Modality | Oligonucleotide |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2025 |
Mechanism of action
Plozasiran is designed to target and degrade apoC-III mRNA in the liver through RNA interference. This results in lower levels of apoC-III protein, which enhances the body's ability to clear triglycerides from the blood.
Approved indications
- familial chylomicronemia syndrome (FCS)
Common side effects
- hyperglycemia
- headache
- nausea
- injection site reaction
Key clinical trials
- Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (PHASE3)
- Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
- A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome (PHASE3)
- Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia (PHASE2)
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis (PHASE3)
- Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) (PHASE3)
- Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (PHASE3)
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Redemplo CI brief — competitive landscape report
- Redemplo updates RSS · CI watch RSS
- Arrowhead portfolio CI